Bambusa Therapeutics to Present Phase 1 Data on Novel Atopic Dermatitis Antibody at ISDS 2025

Bambusa Therapeutics Inc has shared an update. The company announced it will present Phase 1 clinical data for BBT001, a novel bispecific IL-4Rα/IL-31 antibody, at the 6th Inflammatory Skin Disease Summit (ISDS 2025) in New York City. The poster, titled “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBT001, a Novel Bispecific IL-4Rα/IL-31 Antibody: Phase 1 Single-Ascending-Dose Study Results in Healthy Volunteers” (Paper #360), is scheduled for presentation on November 13, 2025, during an evening poster session at The New York Academy of Medicine.

For investors, this update signals continued clinical progress of Bambusa’s lead asset in atopic dermatitis and highlights third-party validation through selection at a specialized dermatology and inflammatory disease conference. While Phase 1 data in healthy volunteers primarily address safety, tolerability, and pharmacokinetics rather than efficacy, positive results could support advancement into patient trials, potentially increasing the asset’s value and partnership prospects. The focus on a bispecific antibody platform targeting IL-4Rα and IL-31 positions the company within a competitive but growing market for biologic therapies in atopic dermatitis, where differentiated safety or efficacy profiles could lead to premium pricing and broader market adoption. Engagement with global key opinion leaders at ISDS 2025 may also strengthen Bambusa’s clinical development strategy and visibility with potential collaborators, though near-term revenue impact will depend on the pace and outcome of subsequent clinical phases.